HeartFlow Initiates PRECISE Randomized Clinical Trial
New trial of more than 2,000 patients will evaluate a precision-testing pathway for coronary artery disease including non-invasive coronary CTA + the HeartFlow Analysis as compared to the conventional pathway for diagnosis REDWOOD CITY, Calif. – December 6, 2018 – HeartFlow, Inc. today announced the start of the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms […]
HeartFlow Receives National Reimbursement Approval in Japan
HeartFlow Analysis to be covered by Japan’s health insurance system, making it more broadly available to patients with suspected coronary artery disease REDWOOD CITY, Calif. – November 14, 2018 – HeartFlow, Inc. today announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved the recommendation by the Central Social Insurance Medical Council (Chuikyo) to provide […]
HeartFlow Analysis Enables Physicians to Confidently and Safely Differentiate Patients in Need of Invasive Treatment and Patients Who Can be Managed Medically for Coronary Artery Disease
Global Studies of Over 8,500 Patients Demonstrate Marked Improvement in Outcomes When Physicians Utilize the HeartFlow Analysis in Diagnosis and Treatment MUNICH, GERMANY, August 25, 2018 – Late-breaking data published and presented today confirm that the non-invasive HeartFlow® FFRCT Analysis enables physicians to effectively differentiate patients in need of coronary stenting or bypass surgery from those who […]
NHS Hospitals Turn to Deep Learning and Advanced Algorithms to Fight Heart Disease
NHS Hospitals Turn to Deep Learning and Advanced Algorithms to Fight Heart Disease
HeartFlow Announces New Commercial Coverage with UnitedHealthcare, Largest Health Insurer in U.S.
HeartFlow Analysis Now Covered for more than 75% of Americans. REDWOOD CITY, Calif. – June 27, 2018 – HeartFlow, Inc. today announced that UnitedHealthcare now covers the HeartFlow FFRCT Analysis, extending access to their 45 million beneficiaries. With this new coverage, more than 235 million people in the United States now have access to the HeartFlow Analysis—significantly advancing HeartFlow’s […]
HeartFlow Analysis Demonstrates Highest Diagnostic Performance for Detecting Heart Disease Compared to Other Non-Invasive Tests
Two New Studies Reinforce Value of the HeartFlow Analysis in Providing Functional Evaluation of Coronary Blockages and Enabling Clinicians to Make Treatment Decisions Paris, France – May 22, 2018 – HeartFlow, Inc. today announced new data from the PACIFIC trial showed that the HeartFlow Analysis had the highest diagnostic performance for detecting coronary artery disease (CAD), the most […]
NHS England to Provide Innovation and Technology Payment (ITP) to Drive Adoption of HeartFlow Analysis in the United Kingdom
HeartFlow Analysis recognized as proven innovation to deliver efficiency and improve quality in healthcare REDWOOD CITY, Calif. – April 10, 2018 – HeartFlow, Inc. today announced that NHS England has chosen the HeartFlow FFRCT Analysis as part of the Innovation and Technology Payment (ITP) program. The HeartFlow Analysis was chosen as a new technology to be funded by ITP through […]
HeartFlow Announces Collaborative Research Agreement with Imperial College London
Joint research in medical imaging and deep learning to help improve treatment planning for patients with heart disease REDWOOD CITY, Calif. – March 7, 2018 – HeartFlow, Inc. today announced that it has entered into a collaborative research agreement with Imperial College London. The collaboration will enable experts from HeartFlow and Imperial to work side-by-side on joint projects […]
HeartFlow Enters into Licensing Agreement with Cedars-Sinai for Coronary Plaque Assessment Technology
AutoPlaque Technology Will Accelerate HeartFlow’s Efforts to Bring Plaque Assessment to the HeartFlow Analysis REDWOOD CITY, Calif. – March 1, 2018 – HeartFlow, Inc. today announced that it has entered into a licensing and technology transfer agreement with Cedars-Sinai in Los Angeles for AutoPlaque technology, a software tool used to detect and characterize coronary artery plaque based on […]
HeartFlow Announces Decision by Centers for Medicare & Medicaid Services to Assign a New Technology Payment Classification to HeartFlow® FFRCT Analysis
CMS assigns hospital payment amount for non-invasive technology to aid diagnosis of suspected coronary artery disease REDWOOD CITY, Calif. – November 6, 2017 – HeartFlow Inc. today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized a New Technology Ambulatory Payment Classification (APC) for the HeartFlow® FFRCT Analysis, a first-of-its-kind non-invasive technology that helps clinicians diagnose […]
